Cilexetil

Summary

Cilexetil (CHEMBL2104038) is a phase-3 clinical-stage small molecule; indicated across 1 condition including hypertensive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 186.25 Da · C10H18O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104038
Name	Cilexetil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	22123692
Molecular formula	C10H18O3
Molecular weight	186.25
InChIKey	VTDCYOLLYVAJSY-UHFFFAOYSA-N

SMILES: CC(C)OC(=O)OC1CCCCC1

IUPAC name: cyclohexyl propan-2-yl carbonate

Also known as: Cilexetil, Cilexetilo, CILEXETIL

Patent coverage: 88 distinct patent families (206 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	3	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00244595	PHASE3	COMPLETED	Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age
NCT00244634	PHASE3	COMPLETED	Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).